Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma

While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCF Skp2 ) promotes proteasomal degradation of the c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2017-03, Vol.31 (3), p.645-653
Hauptverfasser:	Malek, E, Abdel-Malek, M A Y, Jagannathan, S, Vad, N, Karns, R, Jegga, A G, Broyl, A, van Duin, M, Sonneveld, P, Cottini, F, Anderson, K C, Driscoll, J J
Format:	Artikel
Sprache:	eng
Schlagworte:	13/1 13/106 13/109 13/2 13/21 13/31 13/89 38 631/61/212/1728 631/67/69 631/92/507 692/699/1541/1990/804 692/699/67/1059/2326 Bortezomib Cancer Research Cell cycle Critical Care Medicine Cyclin-dependent kinases Dosage and administration Drug resistance Drug therapy Gene expression Genetic aspects Hematology Intensive Internal Medicine Kinases Leukemia Medicine Medicine & Public Health Multiple myeloma Oncology Original original-article Patients Pharmacogenomics Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!